8月28日，康方生物盘中下跌6.32%，报94.8港元，成交额5092.9万港元。消息面上，公司于8月27日盘后发布中期业绩，上半年营收18.06亿元人民币，同比增长27.92%，期内亏损4.47亿元，同比收窄24%，但仍未实现盈利。
值得注意的是，公司此前连续两个交易日因依沃西胆道癌III期研究达主要终点及业绩预期催化累计上涨超14%，本次中报虽显示商业销售收入同比增28.65%、经营现金流转正至2.9亿元，但公司仍处于亏损阶段，市场在利好兑现后出现获利回吐压力。此外，近20个交易日南向资金累计净减持188.35万股，短期资金面偏弱。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.